Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference as follows:

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' First Quarter 2020 Earnings Results Conference Call. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals.

In this article we are going to estimate the intrinsic value of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by taking...

Eagle Pharmaceuticals (NASDAQ:EGRX) shareholders are no doubt pleased to see that the share price has bounced 41% in...

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited ("SymBio") has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion ("RI"), a liquid bendamustine injection with a 10-minute administration time, in Japan. The study’s primary objective is to confirm the safety of the RI product. SymBio expects to obtain regulatory approval in the second half of 2022.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) ("Teva") announced today that on April 27, 2020, the U.S. District Court for the District of Delaware (the "Court") has issued a patent decision in favor of Eagle and Teva for BENDEKA® (bendamustine hydrochloride injection, or bendamustine HCl), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.Quarterly Results Earnings per share decreased 16.83% year over year to $0.84, which beat the estimate of $0.57.Revenue of $46,020,000 lower by 7.56% from the same period last year, which missed the estimate of $51,100,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 11, 2020View more earnings on EGRXTime: 08:02 PM ETWebcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2Fhome%2Fdefault.aspx&eventid=2323967&sessionid=1&key=EDEC468D718914C24824955A2CD88AB4®Tag=&sourcepage=registerTechnicals Company's 52-week high was at $64.94Company's 52-week low was at $33.80Price action over last quarter: Up 25.07%Company Profile Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.See more from Benzinga * Recap: CONSOL Energy Q1 Earnings * CEVA: Q1 Earnings Insights * Apyx Medical: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Q4 2019 Eagle Pharmaceuticals Inc Earnings Call

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today provided an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor ("ER") inhibition and improve patient outcomes.

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), a New Jersey-based pharmaceutical company, today announced that its product RYANODEX® (dantrolene sodium) for injectable suspension inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic, in a controlled in vitro laboratory test. On Tuesday, April 14, Eagle submitted its Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for a Phase 2 clinical trial in partnership with Hackensack University Medical Center to evaluate the efficacy of RYANODEX in patients infected with SARS-CoV-2. Eagle has been in contact with the FDA’s Coronavirus Treatment Acceleration Program ("CTAP") to request potential expedited review of the IND application and aims to begin the clinical trial as soon as possible.

Shares of Gilead and Eagle popped Thursday. A report suggested Gilead's coronavirus treatment, remdesivir, could succeed in clinical testing. Eagle's drug showed promise in lab tests.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows:

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced financial results for the three months ended March 31, 2020.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

Market forces rained on the parade of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shareholders today, when the analysts...